Peak Pharmaceuticals, Inc. Reports 2015 Q3 Financials With Increased Revenue
Company Financials Show Continued Revenue Growth Driven by Sales of Its Canna-Pet(R) Line of Products
(firmenpresse) - BOULDER, CO -- (Marketwired) -- 08/13/15 -- (OTCQB: PKPH) ("Peak Pharma" or the "Company"), an emerging leader in the research, development, sales and marketing of safe, hemp-based supplements, today announced results of operations for the three months ending June 30, 2015, which included Q3 revenues of $317,244, a healthy increase over Q2, with year to date results for the nine months ended June 30, 2015 at $751,313.
Dr. Soren Mogelsvang, President and CEO of Peak Pharmaceuticals, states, "Our Canna-Pet® products continue to perform well in the animal health sector where we specifically target a profitable niche of the Pet Supply market. This financial statement represents our third quarter with revenue from product sales and we are pleased to report healthy returns following a moderate but growing investment in sales and marketing efforts. However, with the recent placement of ads in a variety of media outlets, including industry publications and on the Pandora Radio platform, we are excited for the pending release of our new generation of Advanced capsule and biscuit products."
"Our profitability remains robust," continues Dr. Mogelsvang. "And with the recent transition to a larger scale, cGMP compliant manufacturer, we are well positioned to support the anticipated growth while maintaining our margins. The veterinary market continues to offer tremendous potential while providing us with tactical insights in the areas of legal, regulatory and consumer protection issues. This commercial intelligence continues to be critical to our success and ultimately benefits our shareholders."
All revenues were earned from sales of the company''s Canna-Pet® line of products. The product sales were through the Company''s online e-commerce portal, Amazon, plus select retailers and veterinarians. Cash on hand for the period ending June 30, 2015 was $239,621.
The following summary financial information is derived from our unaudited financial statements contained in our 10-Q for the quarter ended June 30, 2015.
Additional details and notes relating to the Company''s finances and agreements can be found as part of the Company''s continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at . For more information please visit .
(OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based nutraceutical and supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of medicinal hemp and cannabinoid products. For more information visit and follow us on , and .
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company''s business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company''s filings with the SEC, including, the Company''s current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the Food and Drug Administration (FDA). The products and statements mentioned in this release are not intended for humans, or to diagnose, treat, cure, or prevent any disease.
:
Peak Pharmaceuticals, Inc Investor Relations
E:
T: +1 (800) 713-9091
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.08.2015 - 13:33 Uhr
Sprache: Deutsch
News-ID 1379008
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BOULDER, CO
Phone:
Kategorie:
Equipment & Supplies
Anmerkungen:
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peak Pharmaceuticals, Inc. Reports 2015 Q3 Financials With Increased Revenue
"
steht unter der journalistisch-redaktionellen Verantwortung von
Peak Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
